Non-Hodgkin’s Lymphoma - Articles and news items

Sandoz proposed biosimilars recommended for EU approval

Industry news / 25 April 2017 / Niamh Marriott, Junior Editor

CHMP has adopted positive opinions, separately recommending the approval of both Sandoz’s biosimilar rituximab and biosimilar etanercept in Europe…

First biosimilar mAb in oncology granted EU approval

Industry news / 23 February 2017 / Niamh Marriott, Digital Editor

The European Commission has approved Truxima (biosimilar rituximab) for all indications of reference rituximab in the European Union (EU)…

Verastem licenses Duvelisib from Infinity Pharmaceuticals for $28 million

Industry news / 3 November 2016 / Niamh Louise Marriott, Digital Content Producer

Verastem licensed exclusive worldwide rights to develop and commercialise Infinity’s oncology product candidate duvelisib…

Predosing NHL patients with lilotomab before betalutin therapy lowers haematological toxicity

Industry news / 5 September 2016 / Niamh Louise Marriott, Digital Content Producer

RM radiation doses were significantly higher in the patients who did not receive predosing, indicating that pre-dosing with lilotomab has a protective…

Blood cancer study yields disappointing results

Industry news / 19 July 2016 / Niamh Louise Marriott

Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma…

Positive results from Phase III study of Gazyva in follicular lymphoma

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

Results from an interim analysis showed that Gazyva-based treatment significantly reduced the risk of disease worsening or death…

B-cell NHL treatment market to reach $5.45 billion by 2024, says GlobalData

Industry news / 28 January 2016 / Victoria White

GlobalData states that the limited growth in the B-cell NHL treatment market will be hindered by the entry of biosimilars and generics combined with a weak pipeline…

Epizyme releases additional data from Phase 1 study of tazemetostat in non-Hodgkin’s lymphoma

Industry news / 22 June 2015 / Victoria White

Epizyme has reported results from the ongoing Phase 1 trial of tazemetostat in patients with advanced B-cell non-Hodgkin’s lymphoma and solid tumours…

Gazyvaro stalls growth and spread of indolent non-Hodgkin’s lymphoma

Industry news / 1 June 2015 / Victoria White

Results from a Phase III study show that Gazyvaro provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL)…

Non Hodgkin's Lymphoma

Global Non-Hodgkin Lymphoma therapeutics market value to hit $9.2 billion by 2020

Industry news / 29 October 2014 / GBI Research

The global Non-Hodgkin Lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 7.4%, says business intelligence provider GBI Research…

Non Hodgkin's Lymphoma

Non-Hodgkin’s Lymphoma drug market set to double to $8.4 billion by 2019

Industry news, News / 27 April 2011 / Decision Resources

Decision Resources suggests that growth will be driven by the launches of premium-priced therapies…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+